加载中
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
前收盘价
US$1.42
+US$0.05 · +3.65%
盘中时间采用ET。市场数据可能有所延迟。
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
日内区间
当前US$1.42
52周区间
当前US$1.42
盘中时间采用ET。市场数据可能有所延迟。
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
日内区间
当前US$1.42
52周区间
当前US$1.42
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 140.9万 USD | — | — | — | — |
| 毛利 | −140.9万 USD | — | — | — | — |
| 研究与开发 | 6197.9万 USD | 1.18亿 USD | 1.03亿 USD | 6271.3万 USD | 2799.6万 USD |
| 销售、一般及管理费用 | 1932.8万 USD | 2598.5万 USD | 2358.9万 USD | 2092.1万 USD | 1367.1万 USD |
| 营业费用 | 7989.8万 USD | 1.44亿 USD | 1.26亿 USD | 8363.4万 USD | 4166.7万 USD |
| 利息收入 | 185.8万 USD | 564.4万 USD | 888万 USD | 180.6万 USD | 10万 USD |
| 折旧和摊销 | 140.9万 USD | 174.8万 USD | 151.5万 USD | 69.1万 USD | 24.9万 USD |
| 营业利润 | −8130.7万 USD | −1.44亿 USD | −1.26亿 USD | −8363.4万 USD | −4166.7万 USD |
| 净利润 | −6179.7万 USD | −1.38亿 USD | −1.17亿 USD | −8182.8万 USD | −4156.7万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI356.51万0.00%2.3万亿 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF106.54万0.00%954亿 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC29.98万0.02%13.17亿 USD0.60%US$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM12万0.10%1.17亿 USD0.73%US$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
